OKYO Pharma Limited (OKYO)

NASDAQ: OKYO · IEX Real-Time Price · USD
-0.43 (-16.23%)
At close: May 24, 2022 4:00 PM
0.09 (4.05%)
After-hours:May 24, 2022 6:35 PM EDT
Market Cap48.33M
Revenue (ttm)n/a
Net Income (ttm)-5.27M
Shares Out21.77M
EPS (ttm)-0.24
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close2.65
Day's Range2.10 - 2.63
52-Week Range2.10 - 6.11
Price Targetn/a
Earnings Daten/a

About OKYO

OKYO Pharma is a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, which we believe plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical pr...

IPO DateMay 17, 2022
CEODr. Gary S. Jacob
Stock ExchangeNASDAQ
Ticker SymbolOKYO
Full Company Profile

Financial Performance

Financial Statements


OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation

OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases...

1 week ago - GLOBE NEWSWIRE

OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market an...

OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain...

2 months ago - GLOBE NEWSWIRE

Ocular disease biotech OKYO Pharma files for a $12 million US IPO

OKYO Pharma, a preclinical biotech developing a lipidated chemerin analog for dry eye disease, filed on Friday with the SEC to raise up to $12 million in an initial public offering.

2 months ago - Renaissance Capital

OKYO Pharma IPO Registration Document (F-1)

OKYO Pharma has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC

OKYO Pharma announces Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat D...

OK-101 First-in-Human Trial planned as Phase 2 Trial incorporating Primary Efficacy Endpoints covering Signs and Symptoms of Dry Eye Disease

3 months ago - GLOBE NEWSWIRE